Previous studies have suggested MT1G to be involved in tumour suppression in colorectal cancer, hepatocellular carcinoma and papillary thyroid carcinoma, where its loss of expression appears to be epigenetically regulated such as through promoter hypermethylation46, 61, 62, 63. Here, MT1G is linked to hepatocellular carcinoma.